Integer Holdings Corporation $ITGR Shares Sold by Northern Trust Corp

Key Points

• Northern Trust Corp has reduced its holdings in Integer Holdings Corporation by 1.5%, selling 6,417 shares and owning a total of 415,963 shares valued at approximately $49 million.
• Insider selling was notable, with Directors Martin C. Maxwell and Donald J. Spence selling 8,720 and 14,739 shares, respectively, which represented significant decreases in their ownership levels.
• Analysts maintain a consensus rating of Buy for Integer, with a target price average of $140.25, despite recent adjustments to price objectives by several firms.

Northern Trust Corp lessened its stake in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 1.5% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 415,963 shares of the medical equipment provider's stock after selling 6,417 shares during the quarter. Northern Trust Corp owned approximately 1.19% of Integer worth $49,088,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ITGR. Vaughan Nelson Investment Management L.P. purchased a new stake in Integer in the 1st quarter worth $33,337,000. Nuveen LLC acquired a new position in shares of Integer during the 1st quarter valued at about $17,634,000. GAMMA Investing LLC boosted its position in shares of Integer by 8,697.6% during the 1st quarter. GAMMA Investing LLC now owns 78,123 shares of the medical equipment provider's stock valued at $92,190,000 after acquiring an additional 77,235 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Integer during the 4th quarter valued at about $7,889,000. Finally, Natixis Advisors LLC boosted its position in shares of Integer by 117.7% during the 1st quarter. Natixis Advisors LLC now owns 94,202 shares of the medical equipment provider's stock valued at $11,117,000 after acquiring an additional 50,924 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

Wall Street Analyst Weigh In

ITGR has been the topic of several recent research reports. Wells Fargo & Company lowered their price target on shares of Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Truist Financial lowered their price target on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research report on Friday, July 25th. Citigroup raised shares of Integer from a "hold" rating to a "strong-buy" rating and upped their target price for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Wall Street Zen raised shares of Integer from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Raymond James Financial decreased their target price on shares of Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a research report on Friday, July 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $140.25.

Insider Activity at Integer

In other Integer news, Director Martin C. Maxwell sold 8,720 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the transaction, the director directly owned 22,170 shares in the company, valued at $2,672,815.20. This represents a 28.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Donald J. Spence sold 14,739 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the transaction, the director owned 18,781 shares in the company, valued at $2,260,856.78. This represents a 43.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.16% of the company's stock.

Integer Stock Down 0.6%

Shares of ITGR stock traded down $0.66 during trading hours on Tuesday, reaching $107.21. 17,989 shares of the stock were exchanged, compared to its average volume of 468,769. The business's fifty day moving average is $112.48 and its two-hundred day moving average is $117.58. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.41 and a quick ratio of 2.18. Integer Holdings Corporation has a 12-month low of $104.93 and a 12-month high of $146.36. The firm has a market capitalization of $3.76 billion, a P/E ratio of 47.23, a P/E/G ratio of 0.85 and a beta of 1.03.

Integer (NYSE:ITGR - Get Free Report) last released its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The firm had revenue of $476.00 million for the quarter, compared to analysts' expectations of $464.37 million. During the same quarter in the previous year, the company posted $1.30 earnings per share. The firm's quarterly revenue was up 11.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, research analysts expect that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.